Clinical Trial Update: Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA) [NA]

View source ↗

Summary

The document provides an update on a completed clinical trial evaluating epsilon-aminocaproic acid (EACA) to reduce blood loss during total hip arthroplasty.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Joint Disease
• Osteoarthritis

Drugs mentioned

• Epsilon-aminocaproic acid (epsilon-aminocaproic acid)

Snippet

Sponsor: Mayo Clinic | Conditions: Degenerative Joint Disease, Osteoarthritis | NA | Status: COMPLETED